48 completed, 7 terminated, 6 unknown, 3 not yet recruiting. 20 Phase 3, 9 Phase 2, 8 Phase 4, 4 Not applicable, 4 Phase 1.
Follow Candidemia: new trials by email Literature Review of Candidemia trials Research Report on Candidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial Caspofungin only within the study, Caspofungin for 3 days within the study, Placebo only within the study - Candidemia, Invasive Candidiasis | Phase 4 | Not yet recruiting | Oliver Cornely, MD | 420 | 2026-09-01 | 2026-09-01 |
| A Randomized Study of a Short Duration Therapy for Candidemia Standard of Care (SOC), Shortened duration of antifungal therapy - CANDIDEMIA | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 362 | 2025-07-01 | 2025-03-05 |
| A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia Antifungal treatment - Candidemia | Not yet recruiting | Augusta University | 150 | 2025-05-01 | 2025-04-04 | |
| Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI) Beta-1,3/1,6-D-Glucan - Candidemia, Aspergillosis Invasive | Completed | Central Hospital, Nancy, France | 280 | 2024-12-17 | 2025-12-09 | |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| Middle East Study of Infections in Patients With Hematological Malignancies No Intervention: Observational Cohort - Hematological Malignancy, Hematopoetic Stem Cell Transplantation | Recruiting | Hamad Medical Corporation | 1000 | 2024-09-15 | 2026-10-30 | |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| Candida PCR Diagnosis Strategy in Patients From Intensive Care Units Diagnosis strategy based on C. glabrata / krusei PCR - Candida | Not applicable | Completed | University Hospital, Toulouse | 48 | 2022-05-19 | 2026-08-11 |
| Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia Interferon Gamma-1B - Candidemia | Phase 2 | Completed | Radboud University Medical Center | 65 | 2022-03-31 | 2026-06-22 |
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris APX001 - Candidemia, Invasive Candidiases | Phase 2 | Completed | Basilea Pharmaceutica | 9 | 2019-12-13 | 2025-09-16 |
| Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood RaPID/BSI Test - Bacteremia, Candidemia | Unknown | HelixBind, Inc. | 225 | 2019-10-01 | 2019-11-01 | |
| Dosage of Plasma 1, 3-β-D-glucan for the Diagnosis of Candidemia. BDG analysis - Infection, Fungal | Unknown | Assistance Publique - Hôpitaux de Paris | 2000 | 2018-12-12 | 2021-01-26 | |
| Echinocandins Versus Azoles for Candidemia Treatment Echinocandin treatment, Triazole treatment - Candidemia | Completed | Hospices Civils de Lyon | 79 | 2018-11-01 | 2020-03-04 | |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia APX001 - Candidemia | Phase 2 | Completed | Basilea Pharmaceutica | 21 | 2018-10-03 | 2025-09-16 |
| Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) SCY-078 - Candidiasis, Invasive, Candidemia | Phase 3 | Completed | Scynexis, Inc. | 30 | 2017-11-15 | 2024-07-03 |
| Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study Micafungin - Invasive Fungal Infections | Completed | Astellas Pharma Singapore Pte. Ltd. | 120 | 2017-06-21 | 2024-10-21 | |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension CD101, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 207 | 2016-07-26 | 2020-12-08 |
| Bio-assay Development and Implementation for Fungal Infection Detection Candidemia - Candidemia | Withdrawn | Universitaire Ziekenhuizen KU Leuven | 2016-06-01 | 2016-05-12 |
Showing 20 of 69. Sign in to see all of them.
Candidiasis, Invasive (28) · Candidiasis (20) · Torulopsis (13) · Mycoses (12) · Fungemia (8) · Sepsis (7) · Invasive Fungal Infections (5) · Aspergillosis (4) · Bacteremia (3) · Pathologic Processes (2) · Pneumonia, Pneumocystis (2) · Systemic Inflammatory Response Syndrome (2) · Systemic candidiasis (2) · Cross Infection (1)
Bacterial Infections and Mycoses (69) · Pathological Conditions, Signs and Symptoms (69) · Infections (68) · Inflammation (68) · Pathologic Processes (67) · Systemic Inflammatory Response Syndrome (67) · Invasive Fungal Infections (64) · Sepsis (62) · Fungemia (61) · Mycoses (57) · Candidiasis (49) · Candidiasis, Invasive (41) · Bacterial Infections (4) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3)
Anidulafungin (13) · Fluconazole (13) · Micafungin (12) · Caspofungin (8) · Voriconazole (7) · Injections (4) · ibrexafungerp (3) · Rezafungin (2) · liposomal amphotericin B (2) · Amphotericin B (1) · Echinocandins (1) · Interferon-gamma (1) · Standard of Care (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · Veronate (1)
Pfizer (15) · Astellas Pharma Inc (7) · Basilea Pharmaceutica (3) · Scynexis, Inc. (3) · T2 Biosystems (3) · Assistance Publique - Hôpitaux de Paris (2) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Radboud University Medical Center (2) · AM-Pharma (1) · Amsterdam UMC, location VUmc (1) · Astellas Pharma China, Inc. (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Singapore Pte. Ltd. (1) · Augusta University (1) · Bristol-Myers Squibb (1)
United States (33) · France (15) · Germany (13) · Italy (12) · Canada (11) · Belgium (10) · Spain (10) · Greece (8) · Brazil (7) · Netherlands (7) · South Korea (7) · Bulgaria (6) · China (6) · Israel (6) · Russia (6)
David Angulo, MD (3) · Marc Engelhardt (2) · Peter Pappas, MD (2) · Alexandra Hill, MD (1) · Arunaloke Chakrabarti, MD (1) · Barbara D Alexander, MD (1) · Claudia Spies, Prof., MD (1) · Corine Delsing, MD (1) · Daniel Benjamin, MD (1) · Eleonora L Swart, PhD (1) · Francesco G De Rosa, MD (1)
PMID 28459966, PMID 28597967, PMID 33891293, PMID 31280481, PMID 21147825, PMID 23315320, PMID 33438477, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 41940006, PMID 16127033, PMID 17568028, PMID 17719934, PMID 19804626, PMID 22018278, PMID 22879929, PMID 23676114, PMID 23710653, PMID 24559321, PMID 24669841, PMID 25097069, PMID 25586686, PMID 25678411, PMID 25902926, PMID 27287231, PMID 27872072, PMID 29367293, PMID 29438475, PMID 29596222, PMID 30289478, PMID 30418357, PMID 32032174, PMID 32955088, PMID 36442484, PMID 37022196, PMID 37596890, PMID 37773627, PMID 38985561, PMID 39259571, PMID 41194465
2008 (1), 2009 (1), 2015 (1), 2017 (1), U01CK000692 (1)